Abstract
Helicobacter pylori-associated gastric cancer is a major cause of morbidity and mortality worldwide, and is predicted to become even more common in developing countries as the population ages. Since gastric cancer develops slowly over years to decades, and typically progresses though a series of well-defined histologic stages, cancer biomarkers have potential to identify asymptomatic individuals in whom surgery might be curative, or even those for whom antibiotics to eradicate H. pylori could prevent neoplastic transformation. Here we describe some of the challenges of biomarker discovery, summarize current approaches to biomarkers of gastric cancer, and explore some recent novel strategies.
Keywords: :
Disclosure of Potential Conflicts of Interest
No potential conflict of interest was disclosed.
Acknowledgments
Work in the laboratory of J.V.S. on biomarkers of H. pylori-associated gastric cancer is supported by a Public Health Service Award from the NIH (CA R01136647).